Selective cytotoxicity of a novel compound based on Ruthenium II in a Gallbladder carcinoma cell line

Gallbladder cancer (GBC) is highly prevalent in Chile and some southern regions of Colombia. This cancer presents low survival rate and poor prognosis in advanced stages. At this respect, the search for new drugs with better selective activity is necessary, among them ruthenium complexes represent an alternative for the development of more efficient drugs for the treatment of GBC. The objective of this study was to determine the in vitro cytotoxic activity of a novel complex based on Ruthenium (II) on the GBC cell line G-415 vs the non-tumor cell line HEK239 using MTT assay. The cell viability of the experiments showed a significant activity of the treatments in tumor cells.